Connect with us

Features

Is cell-based milk our environmentally friendly alternative to breastfeeding?

Published

on

By replicating milk-producing cells of humans, an Israeli start-up is developing a sustainable breastfeeding alternative to offer nutritional support to infants. 

Wilk develops technologies for producing cell-based milk secreted from mammary epithelial cells, which are found in the mammary glands of both humans and animals. After collecting the mammary gland tissue, the milk-producing cells are isolated from other cells. By creating an ideal and controlled environment, the company then grows cells in a bioreactor and use them to produce sterile, safe, personalised milk ingredients.

In 2021 the Israeli food tech went public on the Tel Aviv Stock Exchange (TASE), becoming the world’s first publicly traded cell-based milk company. Their aim is to help those women who are unable to breastfeed and create an environmentally friendly alternative to animal dairy.

“Breast milk can affect your mind, your brain development, your neuronal development and basically change your behaviour,” says Dr Nurit Argov-Argaman, the company’s CTO from the Department of Animal Sciences at Hebrew University of Jerusalem. “So the best way to feed babies is with their mother’s milk.

“But, there is no technology right now, that can really mimic the complexity of breast milk in terms of the values that it provides. Not just its nutritional values, but also its bioactivities that are very hard to replicate or replace with other foods.

“With our products, we want to deliver a similar alternative to milk compared to what is available right now. Because this is going to be the next generation of breastfeeding without women and we want to support families and communities in bringing the infant formula world much closer to the real thing.”

As an animal scientist, Argov-Argaman has been working on milk, breastfeeding and lactation since 2006 and during this time, she and her team have learned a lot about the challenges of both breastfeeding and the dairy industry as a whole.

“We asked ourselves how we could utilise and leverage our studies in order to improve infant nutrition and make a difference,” she says.

“When I started, the studies and most of the data on mammary glands collected from the lab were very biased towards developments and pathologists. On the other hand, there was a lot of data on milk, as a raw material. So lactation and culturing cells from mammary glands in order to produce milk were things that we couldn’t find [in previous studies].

“This was probably the main obstacle that we had to work around because we needed to find and stabilise the system in order to come up with the technology [of utilising mammary epithelial cells] that we use today,” the CTO explains.

With a growing population estimated to hit 8.6 billion by mid-2030, sustainability and environmental impacts are issues that have to be considered carefully.

“We need to think about the price the environment is paying and how we can reduce and cut greenhouse gas emissions,” thinks Dr Argov-Argaman. “It’s obvious that we will not be able to count only on the traditional dairy manufacturing practices, so we will have to have other alternatives.”

Wilk’s aim is to produce a variety of proteins and components all at once by using the same system. In other words, it can be described as a B2B company that cultivates specific milk ingredients and components that can be then delivered and incorporated in the products of the infant formula industry and the dairy industry.

Dr Argov-Argaman says that: “The easiest way to think about this is by looking at the vegan dairy alternatives. They have usually lower nutritional value, so the texture, the taste and even the way it looks like are not comparable to real dairy products.

“So we can provide our components to the industry in order to improve their products. These ingredients are from a non-animal production system and can be easily incorporated into a vegan alternative, keeping the product vegan and animal-free. The same thing would happen to breast-milk substitutes.”

The company is in its early stages, but the world is getting closer and closer to seeing this technology being widely used. Wilk has already partnerships with one of the biggest dairy companies in Israel and is currently working at expanding them further.

“We’re targeting the most expensive unique, bioactive components, not in terms of the price, but in terms of the nutritional value and the effects they have on the health of the consumer, from infants to kids and adults,” the CTO adds.

So what is she hoping to see in the next fiver years?

“I think we’ll have more capabilities to increase the efficiency of our system and to approach specialised food ingredients. Our dream is to really have an impact on kids and infants because this is close to everybody’s heart and sure, and everybody can get it.

“But we also hope to make a difference for the adults and elderly people out there by offering affordable and high-quality food. All this will be down the road.”

 

Features

‘We need to disrupt the system’- the founder redefining maternal health outcomes through ultrasound technology

Published

on

Blanca Lesmes, co-founder and CEO of TeleScan

The use of ultrasound in pregnancy is vast and has become the standard of care during pregnancy.

Ultrasound scanning machines have become central in the management of the problems of early pregnancy, particularly but not exclusively in the management of women after assisted conception and those with a high risk of miscarriage.

But despite the increasing importance of this imaging technique, the United States is struggling with a shortage of sonographers.

A study published earlier this year found that from 2011 to 2021, the increase in the number of ultrasound exams has significantly outpaced the increase in the number of sonographers.

Furthermore, the increase in demand for sonographers has grown significantly faster than the supply, leading to a shortage and consequent strain on the healthcare system.

To address the shortage, the study suggested that the number of sonography school openings should be increased and the attendant challenges addressed.

While these measures could help, they don’t address a bigger problem, namely performing ultrasounds more effectively and conveniently.

Blanca Lesmes, co-founder and CEO of the telesonography provider TeleScan, says the missing piece is innovation.

“Women’s health has traditionally taken a back seat,” Lesmes tells Femtech World. “When you look at investment dollars globally, the money is not there. It’s an unfortunate state of affairs, but it’s true.

“The way ultrasound is delivered has not changed since it started back in the 70s. However, if we want to have different outcomes for women we need to disrupt the system.”

Improving health outcomes through innovative ultrasound technology

Disruptive thinking, Lesmes says, is key to bringing high-quality prenatal ultrasound care to patients. She believes that focusing on increasing accessibility to maternal health services, like prenatal ultrasounds, would in turn solve the shortage of sonographers and ensure better patient outcomes.

“Most women do want to see their foetus, they want to have that experience. However, if they live in areas that are underserved by specialised healthcare professionals or they have limited access to healthcare facilities, they are less likely to show up.

“By putting a software like TeleScan as close to them in the community as possible, we can enable medical professionals to perform diagnostic ultrasounds remotely, identify high-risk pregnancies and intervene early.”

The winner of this year’s Femtech World Maternity Innovation award, TeleScan is an ultrasound delivery software that allows for remote ultrasounds to occur anywhere.

The tech-enabled solution connects healthcare facilities with remote perinatal sonographers, making ultrasound more accessible and helping providers identify high-risk pregnancies.

“TeleScan allows health professionals to be able to hold a probe with couple of days of training,” explains Lesmes.

“We’re not asking them to be able to do an ultrasound; we’re doing the ultrasound remotely. We essentially capture video clips at the patient bedside but do all of the diagnostics remotely.”

The software, currently set up to serve OB practitioners, family practice providers, radiologists and maternal-foetal medicine specialists, has been shown to reduce examination and report turnaround times, allowing professionals to see more patients and decreasing the time until the next available appointment.

“We’ve served over 2,000 patients and we are seeing the impact,” says Lesmes. “I think for me it wasn’t surprising that we saw the outcome shift but it was surprising that we saw it shift that fast.

“We’ve even had interest from providers from Pakistan, India, Morocco and Brazil. It’s incredible.”

With nine locations already secured in the US, Lesmes and her team are now working to reduce the costs to make the model sustainable globally.

“We are working with Philips and the March of Dimes on a project where we hope we can package more of the remote monitoring piece of it,” the co-founder explains.

“Serving the underserved is not just good for business, but good for our greater human community and if we’re going to have a global impact, we know we have to be at the heart of the community.”

To receive the Femtech World newsletter, sign up here.

Continue Reading

Features

The start-up on a mission to transform metastatic breast cancer management

More than two million women globally were diagnosed with breast cancer in 2022 alone

Published

on

One in eight women in the US will be diagnosed with breast cancer in their lifetime and one in 39 will die from it. Could this start-up have the solution?

Nine years ago, Hollywood actress Angelina Jolie announced in a New York Times op-ed that she’d decided to go public about her elective double mastectomy to “encourage every woman” to think about their own risk of breast cancer.

The article went viral and increased breast cancer awareness around the globe, leading to the so-called “Jolie effect”.

But while campaigns like this have changed the way we talk about breast cancer, they haven’t translated into better patient outcomes.

The World Health Organisation revealed that in 2022 the “burden of breast cancer” caused 670,000 deaths globally.

In the UK, one woman is diagnosed with breast cancer every 10 minutes, leading to nearly 1,000 deaths each month.

Survival rates have indeed improved in many parts of the world and diagnostic methods have come a long way in identifying a tumour’s molecular profile. However, questions remain when it comes to choosing the most effective treatment combination for a particular tumour or patient.

“Oncologists consider multiple factors to determine the treatment strategy: the patient profile, the clinical tumour stage, the pathological tumour grade, the molecular tumour profile, treatment guidelines and study results, and patient-specific contra- indications,” Wolfgang Hackl, translational oncology scientist and founder and CEO of OncoGenomX, tells Femtech World.

“But there is nothing to assess whether a certain treatment works in a specific tumour. Oncologists can only be certain about that after the entire treatment journey, which can take months, sometimes years.”

Without a tool to support clinical decision-making, doctors turn to risk-adapted approaches, extending moderate therapies for low-risk cancers and intensive therapies for high-risk cancers. But this doesn’t solve the problem, says Hackl.

“Many patients are still over-treated for fear of being under-treated,” the founder explains.

“In breast cancer, about 60 per cent of women receiving treatment are over-treated. These patients end up having side effects which means they have to stop treatment. When they stop treatment, they are at risk of recurrence.

“This applies to under-treatment too. Under-treating and over-treating patients can both lead to sub-optimal treatment.”

The solution, however, could be closer that we might expect. PredictionStar, a decision support technology developed by Hackl and his team at OncoGenomX, could potentially transform breast cancer drug development, diagnosis and outcomes, facilitating individualised therapeutic decisions at any stage of the disease trajectory.

Wolfgang Hackl, founder and CEO of OncoGenomX

The tool, which uses AI and machine learning algorithms, identifies whether a certain therapy works in a particular tumour and finds the treatments proven to be the most effective for each patient and their specific tumour.

“It harnesses four patent-pending core technologies,” says Hackl.

“The first technology is an innovative tumour profiling test, the second one is an individualised prediction model, the third one is a digitalisation tool for information sharing without migrating patient data and the fourth one is a reinforcement technology, which helps the algorithm learn from treatment decisions.”

As far as tumour gene tests are concerned, PredictionStar works with standard, unsupervised, or commercial target gene panels, not only expanding their scope but also raising the applicability of test results from an average 65 per cent to more than 80 per cent.

For the first time, Hackl says, oncologists will be able to understand which treatment combination will work the best for a patient and their tumour.

“PredictionStar takes away the uncertainty around breast cancer treatment decisions and increases the likelihood of opting for the most effective treatment combination without delay and without exposing the patient to the side effects of an ineffective treatment.

“The whole technology is designed as an instrument agnostic which can work with any other existing technologies to allow for seamless interactions, irrespective of the systems that already exist in hospitals.”

The fascinating part is that the tool has a feedback loop which means the technology improves, the more information it gets, refining its therapy guidance.

“This is dramatic if you think about it,” says Hackl. “The US, UK and European countries spend hundreds of billions on cancer treatment every year.

“However, data shows that in cancer R&D, the clinical failure rate is about 30 per cent, which means that one out of three phase three clinical studies fails.

“This is a problem because this is the part of the development which generates 70 per cent of the development cost. Based on the data we have, we believe PredictionStar could reduce treatment expenses by at least 20 per cent.”

At a time when healthcare budgets are being squeezed, this reduction would be significant.

“We tend to believe that healthcare costs are a problem of the poor economies, but richer countries struggle with high healthcare costs too,” Hackl points out.

“This is something that has become very clear in recent years. The way healthcare costs are incrementally increasing over time is not sustainable and needs to be addressed.”

With such impressive capabilities, it seems to be only a matter of time before the availability of robust patient data sets extends the scope of PredictionStar to other cancer types. Hackl doesn’t rule this out.

“Currently, we are focusing on breast cancer, but we are intending to roll this out in other cancer entities,” he says.

If everything goes according to plan, PredictionStar could be ready for use in clinical and translational studies in the next 15-18 months, the founder adds.

“OncoGenomX’s data on file suggest that PredictionStar is leading the game and we have good reasons to believe that it has significant potential to improve clinical and economic outcomes beyond today’s achievements.”

Continue Reading

Features

Could an adhesive device be the answer to perineal tears? This start-up thinks so

Published

on

Ditte Marie Fog Ibsen, co-founder and CEO of oasicare

A new device promises to provide midwives with a “third hand”, substantially reducing perineal tears, but could it really work?

“Simply surviving pregnancy and childbirth can never be the marker of successful maternal healthcare”, the World Health Organisation concluded after a damning report revealed that 287,000 women died in 2020 during and following pregnancy.

While maternal mortality rates are down sharply from where they were 20 years ago, research by United Nations shows that progress toward reaching the UN’s sustainable development goal of reducing maternal mortality has stalled.

According to the United Nations Population Fund (UNFPA), every two minutes a woman dies because of complications due to child birth or pregnancy.

But maternal mortality is not the only problem – for every woman who dies, there are about 20 to 30 women who experience injury, infection, or other birth or pregnancy related complication.

“Maternal mortality is only the tip of the iceberg when it comes to maternal health,” says Ditte Marie Fog Ibsen, co-founder and CEO of oasicare, a medical device start-up based in Copenhagen.

“Maternal morbidity is the hidden base, predominantly featured by perineal ruptures.”

Perineal ruptures are extremely common and expected complications of vaginal birth. In the UK, about 85 per cent of women sustain some degree of perineal trauma during childbirth.

Multiple studies have found that some women who experience severe perineal lacerations suffer long term psychological trauma and social isolation. However, the stigma around the topic means that many feel too embarrassed to seek help.

“Postnatal care is mainly focused on women with higher grades of perineal ruptures, downplaying the impact of lower grade ruptures on woman’s quality of life,” says Fog Ibsen.

“Short, medium and long-term complications are fairly common but rarely acknowledged or prioritised in the global health landscape.”

‘Women’s tears are not properly assessed’

Fog Ibsen and her friend, Julia Sand, were working as industrial designers creating solutions for midwifes when they realised the scale of the problem.

“We were trying to help midwifes manage their work-related musculoskeletal symptoms when we came across a even bigger problem: perineal ruptures.

“At the time, we didn’t know much about it, but we knew we had to do something about it.”

The duo began researching the issue and came up with a single-use medical device designed to protect the perineum and reduce uterine ruptures.

The product, which is currently being tested in several hospitals in Denmark, is adhesive and acts like a protective layer that prevents ruptures during childbirth.

“We are essentially trying to replicate the skin so we can prevent ruptures, which tend to happen when the vagina and perineum stretch during birth,” explains Fog Ibsen.

“We’ve made it very simple so that it can be easily applied and easily taken off.”

The interesting part, she says, is that women don’t actually notice it.

“That’s a quite good thing because there’s a lot of attention on the birth. The midwifes were a bit worried initially about the adhesive and whether it could last and stick to different types of skin, but so far it’s been great.”

The midwifes have played a crucial role in the product development process, helping the oasicare team identify issues early on and improve the device.

“We relied on their knowledge to get the balance right so that in the future we can give the product  to people who don’t have the same level of experience, but can still use it to prevent ruptures.

“The product is very easy to cut in, for example, so that midwives can adjust it easily.”

Currently, the team is not allowed to disclose any details about the efficacy of the product but a study, which is expected to conclude later this year, will establish how much the device could reduce ruptures.

“If all the studies go well and we get good data from the hospitals we work with we could see the product on the market in 2025,” says Fog Ibsen.

Her goal, however, is to launch the device outside Denmark where, she says, women desperately need it.

“In Denmark, I think, the midwives are doing a great job, but in other parts of the world the situation is very different. Women’s tears are not properly assessed, which means that despite having suffered serious tears they are being told that everything’s just fine.

“Our goal is to make the product available in countries like India, where a lot of women would benefit from it. It’s a simple device, but it can have such a big impact.”

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.